Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer

Trial Profile

Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Aspirin (Primary) ; Eflornithine/sulindac (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 09 Oct 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top